These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26371779)

  • 1. Mechanisms of breast cancer resistance to anthracyclines or taxanes: an overview of the proposed roles of noncoding RNA.
    Li XJ; Zha QB; Ren ZJ; Tang JH; Yao YF
    Curr Opin Oncol; 2015 Nov; 27(6):457-65. PubMed ID: 26371779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.
    Hayes EL; Lewis-Wambi JS
    Breast Cancer Res; 2015 Mar; 17():40. PubMed ID: 25849966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug transporters in breast cancer: response to anthracyclines and taxanes.
    Kümler I; Stenvang J; Moreira J; Brünner N; Nielsen DL
    Expert Rev Anticancer Ther; 2015; 15(9):1075-92. PubMed ID: 26313418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
    Perez EA
    Breast Cancer Res Treat; 2009 Mar; 114(2):195-201. PubMed ID: 18443902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixabepilone for the treatment of breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming taxane and anthracycline resistance.
    Zelnak A
    Breast J; 2010; 16(3):309-12. PubMed ID: 20408821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
    Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
    Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
    Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
    Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced tumor gene expression changes in human breast cancers.
    Lee SC; Xu X; Lim YW; Iau P; Sukri N; Lim SE; Yap HL; Yeo WL; Tan P; Tan SH; McLeod H; Goh BC
    Pharmacogenet Genomics; 2009 Mar; 19(3):181-92. PubMed ID: 19352302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy regimens in early breast cancer: major controversies and future outlook.
    Joerger M; Thürlimann B
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):165-78. PubMed ID: 23406558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines.
    Comen EA; Fornier MN
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S7-19. PubMed ID: 20805067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-489 regulates chemoresistance in breast cancer via epithelial mesenchymal transition pathway.
    Jiang L; He D; Yang D; Chen Z; Pan Q; Mao A; Cai Y; Li X; Xing H; Shi M; Chen Y; Bruce IC; Wang T; Jin L; Qi X; Hua D; Jin J; Ma X
    FEBS Lett; 2014 May; 588(11):2009-15. PubMed ID: 24786471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells.
    Zhong S; Ma T; Zhang X; Lv M; Chen L; Tang J; Zhao J
    Gene; 2015 Feb; 556(2):113-8. PubMed ID: 25445394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES
    J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.